Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...

The agency had previously recommended against marketing authorization for the Alzheimer's disease but reconsidered after a review.

The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.